Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Chinese herbal helps keep diabetes at bay for people with prediabetes, metabolic abnormalities

24 Jun 2024 bởi

The traditional Chinese medicine compound Jinlida granules, in combination with lifestyle modifications, has shown promise in reducing the risk of progression from impaired glucose tolerance (IGT) to diabetes in individuals with multiple metabolic abnormalities.

Chinese herbal helps keep diabetes at bay for people with prediabetes, metabolic abnormalities

24 Jun 2024

Is T1D protective against Parkinson’s disease?

24 Jun 2024 bởi

Researchers from Singapore found an association between type 1 diabetes (T1D) and Parkinson’s disease (PD) in a Mendelian randomization (MR) study.

Is T1D protective against Parkinson’s disease?

24 Jun 2024

Heart failure carries tenfold increase in kidney disease risk in T2D

23 Jun 2024 bởi

Among individuals with type 2 diabetes (T2D), heart failure is strongly linked to worsening kidney function, such that the risk of end-stage kidney disease (ESKD) soars tenfold following heart failure events, according to a Singapore study.

Heart failure carries tenfold increase in kidney disease risk in T2D

23 Jun 2024

Does paternal use of metformin up risk for congenital malformations?

21 Jun 2024

Use of metformin monotherapy by fathers during the sperm development period prior to conception does not appear to contribute to an increased risk of major congenital malformations (MCMs) in newborns, reveals a study.

Does paternal use of metformin up risk for congenital malformations?

21 Jun 2024

Original New Drug Application Approvals by US FDA (1-15 June 2024)

21 Jun 2024

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 June 2024)

21 Jun 2024

Weekly tirzepatide works for weight loss in Chinese adults with obesity

20 Jun 2024

Once-weekly treatment with tirzepatide at either 10 or 15 mg appears to yield substantial reductions in weight, according to data from the phase III SURMOUNT-CN trial.

Weekly tirzepatide works for weight loss in Chinese adults with obesity

20 Jun 2024

Duodenal switch not necessarily better than RYGB for patients with high BMI

17 Jun 2024

In the treatment of patients with a BMI of 50–60 kg/m2, duodenal switch (DS) appears to result in better weight loss outcomes but also more frequent adverse events, including nutritional complications, as compared with Roux-en-Y-gastric bypass (RYGB), according to an open-label study.

Duodenal switch not necessarily better than RYGB for patients with high BMI

17 Jun 2024

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

10 Jun 2024

Treatment with olezarsen in patients with hypertriglyceridemia and elevated cardiovascular risk results in substantial reductions in triglyceride, apolipoprotein B, and non–high-density lipoprotein cholesterol levels, while having no major safety signals, according to data from the phase IIb Bridge–TIMI 73a study.

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

10 Jun 2024

Gastric fundus ablation targets hunger hormone for weight loss

08 Jun 2024 bởi

Ablating the gastric fundus to reduce the production of the hunger hormone ghrelin helps women curb their appetite and lose body weight in the ABLATE-WEIGHT first-in-human trial.

Gastric fundus ablation targets hunger hormone for weight loss

08 Jun 2024

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

Glucose-lowering drugs such as the glucagon-like peptide-1 receptor agonist (GLP-1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and dipeptidyl peptidase-4 inhibitor (DPP-4i) work better and are more cost-effective than sulfonylureas and glinides (SU) as second-line treatment for type 2 diabetes (T2D), according to a population-based retrospective cohort study.

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Chinese herbal helps keep diabetes at bay for people with prediabetes, metabolic abnormalities

Chinese herbal helps keep diabetes at bay for people with prediabetes, metabolic abnormalities

Is T1D protective against Parkinson’s disease?

Is T1D protective against Parkinson’s disease?

Heart failure carries tenfold increase in kidney disease risk in T2D

Heart failure carries tenfold increase in kidney disease risk in T2D

Does paternal use of metformin up risk for congenital malformations?

Does paternal use of metformin up risk for congenital malformations?

Original New Drug Application Approvals by US FDA (1-15 June 2024)

Original New Drug Application Approvals by US FDA (1-15 June 2024)

Weekly tirzepatide works for weight loss in Chinese adults with obesity

Weekly tirzepatide works for weight loss in Chinese adults with obesity

Duodenal switch not necessarily better than RYGB for patients with high BMI

Duodenal switch not necessarily better than RYGB for patients with high BMI

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

Gastric fundus ablation targets hunger hormone for weight loss

Gastric fundus ablation targets hunger hormone for weight loss

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D